Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 72, Issue 6, Pages 1704-1708Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkx049
Keywords
-
Funding
- Shionogi Co., Ltd.
Ask authors/readers for more resources
Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases. Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline. Broth microdilution plates were used to determine MICs. Results: In total 189 non-fermentative Gram-negative bacteria (107 Acinetobacter baumannii and 82 Pseudomonas aeruginosa) and 282 Enterobacteriaceae (including 244 Klebsiella pneumoniae, 14 Enterobacter cloacae and 11 Providencia stuartii) were studied. For both A. baumannii and P. aeruginosa the MIC90 of cefiderocol was 0.5 mg/L. For K. pneumoniae, E. cloacae and P. stuartii the MIC90 of cefiderocol was 1, 1 and 0.5 mg/L, respectively. Tigecycline was the second most active antibiotic, followed by colistin. Conclusions: Cefiderocol exhibited greater antimicrobial activity in vitro against carbapenem-resistant Gram-negative bacteria than comparator antibiotics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available